These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 26041296

  • 21. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease.
    Emonet SF, Seregin AV, Yun NE, Poussard AL, Walker AG, de la Torre JC, Paessler S.
    J Virol; 2011 Feb; 85(4):1473-83. PubMed ID: 21123388
    [Abstract] [Full Text] [Related]

  • 22. The Virus-Host Interplay in Junín Mammarenavirus Infection.
    Gallo GL, López N, Loureiro ME.
    Viruses; 2022 May 24; 14(6):. PubMed ID: 35746604
    [Abstract] [Full Text] [Related]

  • 23. [Arenavirus research and antiviral candidate].
    Tani H, Shuzo U.
    Uirusu; 2018 May 24; 68(1):51-62. PubMed ID: 31105135
    [Abstract] [Full Text] [Related]

  • 24. Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor.
    Chou YY, Cuevas C, Carocci M, Stubbs SH, Ma M, Cureton DK, Chao L, Evesson F, He K, Yang PL, Whelan SP, Ross SR, Kirchhausen T, Gaudin R.
    J Virol; 2016 May 24; 90(9):4494-4510. PubMed ID: 26912630
    [Abstract] [Full Text] [Related]

  • 25. Arenavirus Quasispecies and Their Biological Implications.
    Grande-Pérez A, Martin V, Moreno H, de la Torre JC.
    Curr Top Microbiol Immunol; 2016 May 24; 392():231-76. PubMed ID: 26472215
    [Abstract] [Full Text] [Related]

  • 26. Mining a Kröhnke Pyridine Library for Anti-Arenavirus Activity.
    Miranda PO, Cubitt B, Jacob NT, Janda KD, de la Torre JC.
    ACS Infect Dis; 2018 May 11; 4(5):815-824. PubMed ID: 29405696
    [Abstract] [Full Text] [Related]

  • 27. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses.
    Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, Kickner SS, Sperzel LE, Jones KF, Warren TK, Amanda Lund S, Kirkwood-Watts DL, King DS, Shurtleff AC, Guttieri MC, Deng Y, Bleam M, Hruby DE.
    Antiviral Res; 2006 Feb 11; 69(2):86-97. PubMed ID: 16343651
    [Abstract] [Full Text] [Related]

  • 28. Novel antiviral strategies to combat human Arenavirus infections.
    Kunz S, de la Torre JC.
    Curr Mol Med; 2005 Dec 11; 5(8):735-51. PubMed ID: 16375709
    [Abstract] [Full Text] [Related]

  • 29. Reporter-Expressing, Replicating-Competent Recombinant Arenaviruses.
    Martínez-Sobrido L, de la Torre JC.
    Viruses; 2016 Jul 20; 8(7):. PubMed ID: 27447662
    [Abstract] [Full Text] [Related]

  • 30. High-content image-based screening of a signal transduction pathway inhibitor small-molecule library against highly pathogenic RNA viruses.
    Mudhasani R, Kota KP, Retterer C, Tran JP, Tritsch SR, Zamani R, Whitehouse CA, Bavari S.
    J Biomol Screen; 2015 Jan 20; 20(1):141-52. PubMed ID: 25342145
    [Abstract] [Full Text] [Related]

  • 31. Development of live-attenuated arenavirus vaccines based on codon deoptimization.
    Cheng BY, Ortiz-Riaño E, Nogales A, de la Torre JC, Martínez-Sobrido L.
    J Virol; 2015 Apr 20; 89(7):3523-33. PubMed ID: 25589652
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of arenavirus infection by a glycoprotein-derived peptide with a novel mechanism.
    Spence JS, Melnik LI, Badani H, Wimley WC, Garry RF.
    J Virol; 2014 Aug 20; 88(15):8556-64. PubMed ID: 24850726
    [Abstract] [Full Text] [Related]

  • 33. Potent inhibition of arenavirus infection by a novel fusion inhibitor.
    Gowen BB, Naik S, Westover JB, Brown ER, Gantla VR, Fetsko A, Dagley AL, Blotter DJ, Anderson N, McCormack K, Henkel G.
    Antiviral Res; 2021 Sep 20; 193():105125. PubMed ID: 34197863
    [Abstract] [Full Text] [Related]

  • 34. Arenavirus reverse genetics for vaccine development.
    Ortiz-Riaño E, Cheng BYH, Carlos de la Torre J, Martínez-Sobrido L.
    J Gen Virol; 2013 Jun 20; 94(Pt 6):1175-1188. PubMed ID: 23364194
    [Abstract] [Full Text] [Related]

  • 35. A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding.
    Capul AA, de la Torre JC.
    Virology; 2008 Dec 05; 382(1):107-14. PubMed ID: 18929379
    [Abstract] [Full Text] [Related]

  • 36. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.
    Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB.
    Antiviral Res; 2016 Feb 05; 126():62-8. PubMed ID: 26711718
    [Abstract] [Full Text] [Related]

  • 37. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.
    Lee N, Shum D, König A, Kim H, Heo J, Min S, Lee J, Ko Y, Choi I, Lee H, Radu C, Hoenen T, Min JY, Windisch MP.
    Antiviral Res; 2018 Oct 05; 158():226-237. PubMed ID: 30149038
    [Abstract] [Full Text] [Related]

  • 38. Screening and identification of Lassa virus endonuclease-targeting inhibitors from a fragment-based drug discovery library.
    Lan X, Zhang Y, Jia X, Dong S, Liu Y, Zhang M, Guo J, Cao J, Guo Y, Xiao G, Wang W.
    Antiviral Res; 2022 Jan 05; 197():105230. PubMed ID: 34965446
    [Abstract] [Full Text] [Related]

  • 39. Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps.
    Kerber R, Reindl S, Romanowski V, Gómez RM, Ogbaini-Emovon E, Günther S, ter Meulen J.
    J Clin Virol; 2015 Mar 05; 64():120-7. PubMed ID: 25549822
    [Abstract] [Full Text] [Related]

  • 40. [Arenavirus infections].
    Tani H, Fukushi S, Yoshikawa T, Saijo M, Morikawa S.
    Uirusu; 2012 Mar 05; 62(2):229-38. PubMed ID: 24153233
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.